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Abstract
Background: Studies have been shown that miR-125a plays an important role in carcinogenesis, however, the role of miR-
125a in hepatocellular carcinoma (HCC) remains elusive.
Methodology/Principal: Real time-PCR (qRT-PCR) was performed to test the significance of miR-125a in HCC. Ectopic
expression of miR-125a was used to test the influences of miR-125a on proliferation and metastasis of HCC cells in vitro and
in vivo. Predicted target genes of miR-125a were determined by dual-luciferase reporting, qRT-PCR, and western blot (WB)
analyses. Then immunohistochemical staining (IHC) was used to detect the expression of target genes, and the correlations
and prognostic values of miR-125a and its target genes were also investigated.
Conclusions/Significance: Decreased miR-125a was observed in both HCC tissues and cell lines, and associated with
patients’ aggressive pathologic features. Up-regulating miR-125a significantly inhibited the malignant phenotypes by
repressing the expression of matrix metalloproteinase 11 (MMP11) and vascular endothelial growth factor A (VEGF-A) both
in vitro and in vivo. Furthermore, miR-125a expression was inversely correlated with both MMP11 and VEGF-A expression in
HCC tissues. Inhibiting miR-125a could increase both MMP11 and VEGF-A expression, and RNA interference targeting
MMP11 or VEGF-A mRNA could rescue the loss of miR-125a functions. MiR-125a inhibits the proliferation and metastasis of
HCC by targeting MMP11 and VEGF-A. Up-regulation of miR-125a might be a promising approach and a prognostic marker
for HCC.
Citation: Bi Q, Tang S, Xia L, Du R, Fan R, et al. (2012) Ectopic Expression of MiR-125a Inhibits the Proliferation and Metastasis of Hepatocellular Carcinoma by
Targeting MMP11 and VEGF. PLoS ONE 7(6): e40169. doi:10.1371/journal.pone.0040169
Editor: Chun-Ming Wong, University of Hong Kong, Hong Kong
Received February 28, 2012; Accepted June 4, 2012; Published June 29, 2012
Copyright:  2012 Bi et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by National Basic Research Program of China (No. 2010CB732400) and National Natural Science Foundation of China
(No. 30973428, 30900674 and 30970149). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the
manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: dingjie@fmmu.edu.cn (JD); shiyquan@fmmu.edu.cn (YS)
. These authors contributed equally to this work.
Introduction
Hepatocellular carcinoma (HCC) is the second most frequent
cause of cancer death worldwide, and half of HCC diagnoses and
deaths were estimated to occur in China [1]. Despite improve-
ments in surgery and other treatments, the postoperative prognosis
of HCC patients is still unsatisfactory due to the high rate of
recurrence and metastasis. Therefore, identifying the malignant
factors and understanding the mechanisms are critical for the
improvement of therapeutic strategies for HCC patients.
MicroRNAs (miRNAs) are small non-protein-coding RNAs of
20–24 nucleotides that can down-regulate the expression of their
target genes through binding to the 39 untranslated regions
(UTRs) of target mRNAs, resulting in mRNA degradation and
translation inhibition [2,3]. Several miRNAs have been identified
to be abnormally expressed, and to be associated with the
malignant progressions of various human cancers [4,5,6].
MiRNAs were recently found to be frequently down-regulated
in HCC, and they were also shown to be associated with the
carcinogenesis, metastasis, recurrence and prognosis of HCC
[7,8,9,10]. However, further investigation is needed to define the
molecular mechanisms underlying the effects of miRNAs on the
development of HCC. Previous studies have demonstrated that
several miRNAs that are located in fragile sites or aberrant
genomic regions play oncogenic or suppressive roles in the
progression of human cancers [4]. MiR-125a is located at 19q13,
which is frequently deleted in several human cancers. MiR-125a
over-expression impaired the anchorage-dependent growth,
migration and invasion of breast cancer cells by down-regulating
ERBB2 and ERBB3 in the ERBB2-dependent SKBR3 cell line
[11]. Researchers showed that miR-125a could inhibit the
proliferation of human gastric cancer cells in combination with
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regulated in non-small cell lung cancer and had inverse effects
on the invasion and migration of lung cancer cells [13].
Overexpression of miR-125a induces conversion of highly
invasive ovarian cancer cells from a mesenchymal to an epithelial
morphology, suggesting that miR-125a is a negative regulator of
EMT [14]. However, the expression and roles of miR-125a in
HCC have not been studied, nor the prognostic value and co-
expression of miR-125a with target genes in tumor samples from
patients have rarely been investigated.
In the present study, we found that the miR-125a was
frequently down-regulated in HCC compared with matched
adjacent liver tissues, and was correlated with the malignant
progressions of patients. Ectopic expression of miR-125a could
repress the proliferation and metastasis of HCC cell lines both in
vitro and in vivo. However, over-expression of miR-125a could not
significantly down-regulate the expression of ERBB2 or ERBB3 in
HCC cells. Therefore, further studied were needed to elucidate the
mechanisms underlying the inhibitory effects of miR-125a on
HCC cells, and the prognostic values and co-expression of miR-
125a with target genes in tumor samples from patients were also
investigated.
Materials and Methods
Cell Lines and Human Samples
Human HCC cells (SMMC7721, MHCC97L, MHCC97H and
HCCLM3) were kindly provided by Dr. Tang ZY (Liver Cancer
Institute, Zhongshan Hospital, Fudan University, Shanghai,
China) [15]. HepG2 cell line was obtained from American Type
Culture Collection (ATCC number: HB-8065, Manassas, VA).
QZG cell line was obtained from the Cell Research Institute of the
Chinese Academy of Sciences (Shanghai, China), and both of
them are maintained in our lab [16]. All of the cell lines were
cultured in Dulbecco’s modified Eagle medium (DMEM)
supplemented with 10% FBS, 100 mg/ml penicillin, and
100 mg/ml streptomycin at 37uC in a 5% CO2 incubator. Fresh
cancerous and matched adjacent liver tissues were obtained from
80 patients who received primary HCC resection between January
2006 and December 2006 at the Department of General Surgery
in Xijing Hospital (Xi’an, China). The tissues were immediately
frozen in liquid nitrogen after surgical removal and stored at
280uC until use. Paraffin-embedded HCC tissues from the 80
patients were also obtained from Department of Pathology at
Xijing Hospital. This study was approved by the Hospital’s
Protection of Human Subjects Committee, and informed consent
was also obtained from all patients.
RNA Extraction and Real Time-PCR Analysis (qRT-PCR)
Total RNA was extracted from cell lines and tissue samples
using Trizol (Invitrogen), and the concentration of total RNA was
quantitated by measuring the absorbance at 260 nm. The
miScript SYBR
H Green PCR Kit from QIAGEN was used for
qRT-PCR analysis. Primers of miR-125a and U6 snRNA (internal
control) were also purchased from QIAGEN (MS00003423 and
MS00033740). The fold-change for mRNA in HCC tissues
relative to the adjacent non-tumor (NT) tissues was calculated
using the 2
2DDCT method [17], where DDCt=DCt HCC/NT and
DCt=Ct miR-125a-Ct U6. The relative mRNA levels of genes in
HCC cells were also determined by qRT-PCR, and the expression
of GAPDH was used as the internal controls. Each PCR was
performed in triplicate. The primers for the genes examined were
presented in Table 1.
Plasmids Construction and Transfection
Lentivirus-mediated miR-125 was constructed as described in
a previous study [17]. The precursor sequence of miR-125a was
generated as follows: (Forward) 59-CTATGTTTGAATGA
GGCTTCAG-39 and (Reverse) 59-
CGCGTCGCCGCGTGTTTAAACG-39 [18]. The sequence
targeting MMP11 for mRNA interference was 59-ATGTC-
CACTTCGACTATGATG-39; targeting VEGF-A was (59-AU- Table 1. Primers for 39UTR of target genes.
Target genes Primers
MMP11 F 59CTAG ACTAGT CGAGCCTGCCAACACT 39
R 5’CCC AAGCTT GGGATACAGCAAGGACAC 39
ERBB2 F 5’CTAG ACTAGT AGGGAAGAATGGGGTCGT 39
R5 9 CCC AAGCTT GATGCCAGCAGAAGTCAGG 39
EDN1 F 5’ CTAG ACTAGT TGGGGATGACAATGGACC 3’
R 5’ CCC AAGCTT TGGGAAGAGTTTGGGGAG 3’
VEGF F 59 CTAG ACTAGT AGATGTGACAAGCCGAGG 39
R5 9 CCC AAGCTT GTCTACAGGAATCCCAGAAATA 39
ERBB3 F 5 `CTAG ACTAGT GGCAACGAGATGGAGGTGGT 39
R5 9 CCC AAGCTT GGGAATAGGGAGAAGACGGT 39
MMP14 F 59 CTAG ACTAGT TGCTCTACTGCCAGCGTTCC 39
R 5’ CCC AAGCTT TGACCCCATTTGACCTTTA 3’
BCL9L F 5’ CTAG ACTAGT AATCGGGGAAACAGCATC 3’
R 5’ CCC AAGCTT GGACAAACACCCAGTCGTAT 3’
VEGF-Del F 5’ GAAGGAGCCTCCTTTCGGGAACCAGATCT 3’
R 5’ TGGTTCCCGAAAGGAGGCTCCTTCCTCCT 3’
MMP11-Del F 5’ ATATTCGTGGCCTGGCAGGGGTCAGCA 3’
R 5’ GTCAGCATCAGAGGAAAGTGTTGGCA 3’
doi:10.1371/journal.pone.0040169.t001
Table 2. Primers for qRT-PCR.
Genes Primers
MMP11 F 59 TCCTGACTTCTTTGGCTGTG 39
R5 9 CCATGGGTCTCTAGCCTGAT 39
MMP9 F 59 TCCAGTACCGAGAGAAAGCC 39
R5 9 GCAGGATGTCATAGGTCACG 39
MMP14 F 5’ CACAAGGACTTTGCCTCTGA 3’
R 5’ CAGAGAGAAGCAAGGAGGCT3’
VEGF F 59 TCCCGGTATAAGTCCTGGAG 39
R5 9 ACAAATGCTTTCTCCGCTCT 39
BCL9L F 5’GCTTCCCTCTCTCTTTCCCT 39
R 5’ CCTCTCAGAGCCAAGAGGAC 3’
MMP2 F 5’ TGAGAAGGATGGCAAGTACG3’
R 5’ TCAGTGGTGCAGCTGTCATA3’
ERBB2 F59 CAGAGTACCATGCAGATGGG 39
R5 9 CATCACTCTGGTGGGTGAAC 39
GAPDH F59 GCACCGTCAAGGCTGAGAAC 39
R5 9 TGGTGAAGACGCCAGTGGA 39
doi:10.1371/journal.pone.0040169.t002
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125a was (59-UCCCUGAGACCCUUUAACCUGA-39 ). These
siRNAs were synthesized and inserted into the Pgene sil-1 vector.
The empty vector (without miR-125a or siRNA) was used as
a negative control. All of the vectors also encoded green
fluorescent protein (GFP).
The miR-125a or the negative control virus was infected into
HepG2 and HCC-LM3 cell lines respectively. The siRNA
targeting the mature miR-125a and control were transfected into
SMMC7721 cells, which showed relatively high miR-125a
expression in HCC cell lines, and the successfully transfected cells
were named si-7721 and con-7721. The successfully transfected,
GFP-positive cells were separated by flow cytometry (FACScan;
Becton Dickinson, San Jose, CA). The purified, GFP-positive cell
lines were named HepG2-125a, HepG2-NC, LM3-125a, LM3-
NC, Si-7721 and Con-7721. Then MMP11, VEGF-A and the
control siRNA were transfected into si-7721 cells, and named Si-
MMP11, Con-MMP11, Si-VEGF and Con-VEGF.
MTT Assay
MTT assays were performed to evaluate the speed of cell
proliferation as described previously [19]. Briefly, log phase cells
were trypsinized into a single cell suspension and seeded into 96-
well plates at a density of 1610
3 cells/well. After 1, 2, 3, 4, 5, 6 or
7 days of cell cultivation, 20 ml of 3-(4,5)-dimethylthiahiazol (-z-
y1)-3,5-di-phenytetrazo-libromide (MTT, 5 mg/ml; Sigma, St.
Louis, MO) was added into each well and incubated for 4 hours at
37uC. The supernatant was then aspirated, and 150 ml dimethyl-
sulfoxide (DMSO) was added to dissolve the crystals with agitation
for 10 minutes at room temperature. The absorbance values were
measured using an ELISA reader (Bio-Rad Laboratories,
Richmond, CA) at a wave length of 490 nm. Each experiment
was repeated three times.
Soft Agar Assay
Soft agar assays were performed to evaluate the in vitro
tumorigenicity of cells. Approximately 2610
3 cells from each cell
line were seeded in 0.3% agarose with a 0.5% agarose underlay in
a six-well plate. The cells in agarose were cultured at 37uCi na n
atmosphere of 5% CO2 at mosphere for 17 days. Cell colonies
were counted by two independent observers. Each cell line was
tested in triplicate, and the results shown are the mean of three
repeated experiments.
Cell Invasion and Migration Assays
Cell migration and invasion assays were performed as described
by others [20]. For migration assays, HepG2-125a, HepG2-NC,
LM3-125a and LM3-NC cells were cultured in DMEM with 0.1%
FBS. After 24 h, 2610
5 starved cells in DMEM without FBS or
HGF were plated in the upper chamber with a non-coated
membrane (6.5 mm in diameter, 8-lm pore size; Corning, NY,
USA). For invasion assays, the chambers used were coated with
200 mg/ml of Matrigel and dried for 12 h. Then, 2610
5 cells
were added to the top chamber. For both invasion and migration
Figure 1. Down-regulation of miR-125a in HCC tissues and cell lines. The expression of miR-125a in tissues and cell lines was detected by
qRT-PCR analysis, and the results shown are the mean value of three repetitions calculated by 2
2ggCt with U6 snRNA as the internal control. (A) MiR-
125a expression in 80 HCC and paired adjacent non-tumor liver tissues. A significantly lower expression level of miR-125a was observed in HCCs
compared with that in adjacent liver tissues (P=0.005). (B) Relative fold changes of miR-125a in HCC cell lines compared to the normal Liver cell line
QZG.
doi:10.1371/journal.pone.0040169.g001
Table 3. MiR-125a and MMP11 expression correlated with
clinical features of patients.
MiR-125a P value MMP11 P value
Parameter Group Low High – +
Age ,56 20 20 1.00 18 22 0.36
.56 20 20 14 26
Gender Male 28 28 0.64 18 36 0.08
Female 12 14 14 12
HBV 2 5 9 0.24 9 5 0.05
+ 35 31 23 43
Metastasis Without 17 32 0.001 26 23 0.003
With 23 8 6 25
AFP Low 19 21 0.37 18 22 0.36
High 21 19 14 26
T stage I+II 10 27 ,0.001 19 18 0.06
III+IV 30 13 13 30
The associations of miR-125a and MMP11 with clinical features were detected
by Kruskal-Wallis H or Mann–Whitney U test. *P , 0.05 was considered
statistically significant.
doi:10.1371/journal.pone.0040169.t003
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into the lower chamber. After 24 h at 37uC, the cells on the upper
membrane surface were carefully removed. After incubation with
95% ethanol for 20 min, the filters were stained with 0.2% crystal
violet solution for 10min, and counted using an inverted
microscope. The results presented are the mean of three
independent assays.
Luciferase Reporter Assay
For dual luciferase assays, HepG2-125a or HepG2-NC cells in
24-well plates were co-transfected with 0.4 mg of the firefly
luciferase report vector and 0.08 mg of pRL-TK control vector
containing Renilla luciferase (Promega) using siPORTneoFX
(Ambion, Austin, TX) according to the manufacturer’s protocol.
Lysates were prepared at 48 h post-transfection. Luciferase activity
was measured using the Dual-Light luminescent reporter gene
assay (Applied Biosystems). Firefly luciferase activity was normal-
ized to renilla luciferase activity for each transfected well. Three
independent experiments were performed in triplicate. The
primers for the 39-UTR of targets containing a miR-125a binding
site are shown in Table 2.
Western Blot Analysis
Western blot assays were performed as described in our
previous study [19]. Total protein was separated using sodium
dodecyl sulfate–polyacrylamide gel electrophoresis and transferred
to nitrocellulose membrane (Bio-Rad, Hercules, CA). The
membranes were blocked with 10% nonfat milk in TBS-T and
incubated with mouse anti-MMP11 (Cell Signaling Technology,
1:300), rabbit anti-VEGF (Santa Cruz, 1:200), rabbit anti-ERBB2
(Cell Signaling Technology, 1:500), rabbit anti-ERBB3 (Cell
Signaling Technology, 1:500) or mouse anti-b-actin (Sig-
ma,1:4000) antibodies. The levels of goal protein were detected
Figure 2. Inhibition of cell proliferation by ectopic expression of miR-125a in vitro and in vivo. (A) qRT-PCR analysis confirmed that miR-
125a expression was significantly up-regulated in HepG2-125a and LM3-125a cells compared with matched controls. U6 snRNA was used as the
internal control. (B) The growth curves are plotted based on the MTT assay results. The data presented are the mean value of three repetitive
determinations. (C) The colony numbers shown are the mean of three repetitions, and are expressed as the mean 6 SD. (D) In vivo tumorigenicity in
nude mice. HepG2-125a or LM3-125a cells were injected into the right flanks and their matched controls were injected into the left flanks of mice.
Four weeks later, the tumors were resected from the mice, and calculated using the formula: L6S2 /2. (E and F) qRT-PCR and western blot showed
that the expression of miR-125a in the tumor from right flank were significantly lower that the left flank. Inversely, both the expression of MMP11 and
VEGF-A were significantly higher in the right flank were significantly lower that the left flank (Fig. 2 E and F). *P,0.05 VS matched controls.
doi:10.1371/journal.pone.0040169.g002
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b-actin was used as an internal control.
Immunohistochemical Staining (IHC)
IHC was used to detect the MMP11 and VEGF expression in
HCC tissues as described in our previous work [19]. After being
blocked with 3% H2O2, sections were incubated overnight at
4uC with antibodies (MMP11, 1:50;VEGF, 1:100) diluted in
phosphate buffered saline (PBS). After three 5-min washes with
PBS-T, sections were incubated with biotinylated goat anti-Rb or
mouse IgG/HRP (1:2000, Zhongshan) for 1h, followed by three
additional 5-min washes with PBS-T. DAB solution was used for
visualization of the samples. As a negative control, the primary
antibody was replaced with PBS. As in previous study, scores of
0 and 1 were considered to represent negative expression, and 2
and 3 were considered to represent positive expression [11].
Animal Experiments
Athymic mice (4–5 weeks old) were purchased from the Animal
Center of the Chinese Academy of Science (Shanghai, China) and
maintained in laminar ow cabinets under specific pathogen-free
conditions. A total of 10 mice were used for the subcutaneous
study. HepG2-125a or LM3-125a cells were injected into the right
anks, and HepG2-NC or LM3-NC cells were injected into the left
flanks. Four weeks after inoculation, the tumor-bearing mice were
sacrificed, and the tumor volumes were calculated following the
formula: L6S2 /2. Moreover, the total RNA and protein of each
representative tumor from mice were used for analyses of the
expression levels of miR-125a, MMP11 and VEGF-A target genes
by qRT-PCR and western blot.
Previous studies have demonstrated that HCC-LM3 is a highly
invasive cell line that can be used for in vivo metastasis assays
[15], therefore, LM3-125a and LM3-NC cells were chosen for
the metastasis experiments. Approximately 2610
6 cells from
each cell line were suspended in 0.2 ml sterile PBS and injected
into the tail veins of 10 mice. The mice were sacrificed 6 weeks
after injection. After the visible tumors numbers in the liver and
lung surface were counted, histological examinations were
performed.
Figure 3. Suppression of cell invasion and metastasis in vitro and in vivo by over-expression of miR-125a. (A and B) Migration and
invasion assays confirmed that the invasive abilities of HepG2 and HCC-LM3 cells were significantly inhibited by ectopic expression of miR-125a. The
data presented are the mean of three independent experiments. *P,0.05 VS each control. (C) LM-125a and LM3-NC cells were used for the in vivo
metastasis assays. The pictures shown are the representative anatomical photos of livers and lungs from mice injected with LM-125a or LM3-NC cells.
(D) The data presented are the incidences of metastasis in both the livers and lungs of mice.
doi:10.1371/journal.pone.0040169.g003
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All statistical analyses were carried out using the SPSS 16.0
software package (SPSS, Chicago, IL), and variables with a value
of P,0.05 were considered to be statistically significant. The
differential expression of miR-125a in HCC and paired non-
cancerous tissues was analyzed using the Wilcoxon rank sum test.
The Kruskal–Wallis H test or the Mann–Whitney U test was used
to investigate the significance of miR-125a, VEGF-A and MMP11
expression as correlated with clinical features in HCC. A one-way
ANOVA test was utilized to evaluate the difference between three
comparisons in cell proliferation and soft agar clonogenic assays,
and the least significant difference-T test was used for the analysis
of two groups. Overall survival curves were plotted using the
Kaplan-Meier method and were evaluated for the statistical
significance using a log-rank test.
Results
MiR-125a was Down-regulated in HCC Tissues and Cell
Lines
The expression of miR-125a in HCC and paired adjacent non-
tumor liver tissues from 80 patients was detected using qRT-PCR.
The results showed that miR-125a expression was decreased in
77.5%(62/80)of HCC tissues compared with matched adjacent
liver tissues, with an average of 4.72-fold reduction in expression
(median= 0.37 vs 0.95; P = 0.005; Fig. 1A). Further analysis
revealed that lower expression of miR-125a in HCC was
significantly correlated with the patients’ clinical features, in-
cluding T stage and tumor metastasis (Table 3; P , 0.05).
Consistent with the results observed in tissues, significantly
decreased expression of miR-125a was observed in all five HCC
cell lines (SMMC-7721, HepG2, MHCC-97L, MHCC-97H and
HCC-LM3) compared with the QZG cells (Fig. 1B). MiR-125a
expression was low in SMMC-7721 and HepG2 cells, but barely
in highly invasive cell lines, such as MHCC-97L, MHCC-97H
and HCC-LM3. Therefore, we chose the HepG2 and HCC-LM3
cell lines for further study.
Ectopic Expression of MiR-125a Inhibited HCC Cell
Proliferation
To investigate the effects of miR-125a on the proliferation of
HCC, HepG2 and HCC-LM3 cell lines were used for the
lentivirus-mediated miR-125a transfection. As presented in
Figure 2A, qRT-PCR analysis confirmed that miR-125a was
markedly up-regulated in both HepG2-125a and LM3-125a cells
compared with controls. MTT assays were performed to test the
effects of miR-125a on cell growth. Both HepG2-125a and LM3-
125a cells exhibited much slower growth than their corresponding
controls, and the inhibitory effects showed statistical significance
Figure 4. Inhibition of miR-125a promoted the proliferation and invasion of SMMC-7721 cells. (A) qRT-PCR analysis showed that miR-
125a was significantly down-regulated by lentivirus mediated siRNA targeting mature miR-125a. (B) Down-regulation of miR-125a could significantly
increase the growth of SMMC-7721 cells. (C) Both invasion and migration assays demonstrated that down-regulation of miR-125a could significantly
promote the migration and invasion of cells.
doi:10.1371/journal.pone.0040169.g004
MiR-125a and HCC
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results showed that ectopic expression of miR-125a markedly
decreased the colony numbers of HepG2 and HCC-LM3 cells
(Fig. 2C; P,0.01). These data were further strengthened by the
results from the nude mice tumorigenicity experiments. Four
weeks after subcutaneous injection, tumors appeared much smaller
at the sites injected with HepG2-125a or LM3-125a cells
compared with each control (Fig. 2D; P , 0.01). Thus, the
over-expression of miR-125 may inhibit the tumorigenicity of
HCC cells in vitro and in vivo. Moreover, the total RNA and protein
of each representative tumor from mice were used for analyses of
the expression levels of miR-125a, MMP11 and VEGF-A target
genes by qRT-PCR and western blot. The result showed that the
expression of miR-125a in the right flanks were significantly lower
Figure 5. MiR-125a inhibits cell proliferation and metastasis by directly targeting VEGF-A and MMP11. (A) Dual luciferase assays were
performed in HepG2-125a and HepG2-NC cells transfected with the firefly luciferase report and the control vectors containing Renilla luciferase. The
result showed that miR-125a could significantly suppress the luciferase activity of reporters containing the 39UTRs of MMP11 and VEGF, but has no
significantly effect on reporters containing the 39UTRs of Bcl-9L, EDN1, MMP14, Her2, ERBB2 or ERBB3 in HCC cells. The data shown are the means6SE
of three independent experiments. (B) Assessment of the specificity of binding site. A Reduction of luciferase activity driven by the MMP11 and VEGF
39UTR constructs was observed in HepG2-125a cells co-transfected with pMir-39UTR, but not in cells co-transfected with pMIR-39UTR-D. (C) The
sequences of the miR-125a binding sites within the VEGF-A and MMP11 39UTRs were presented. (D) qRT-PCR analysis shows that the VEGF-A and
MMP11 mRNAs, but not others, were significantly decreased in HepG2-125a cells compared with HepG2-NC cells. (E) Western blot analysis confirmed
that miR-125a significantly inhibited the endogenous expression of VEGF-A and MMP11, but not ERBB3 or ERBB2. b-actin was used a the loading
control. (F) Down-regulation of miR-125a was significantly associated with high expression levels of VEGF-A and MMP11 in HCC clinical samples.
Positive VEGF-A and MMP11 expression was observed in the samples with low miR-125a expression (left), and negative staining for VEGF-A and
MMP11 was observed in samples with high miR-125a expression (right). (G) Western blot analysis shows that miR-125a exhibited a dose-dependency
on MMP11 and VEGF-A expression in HCC-LM3 cells, and the MOI of 50 showed the best effect. *P,0.05 VS control.
doi:10.1371/journal.pone.0040169.g005
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VEGF-A were significantly higher in the right flanks were
significantly lower that the left flanks (Fig. 2 E and F).
Over-expression of MiR-125a Repressed HCC Cell
Invasion and Metastasis
Because the low expression levels of miR-125a in HCC patients
were markedly correlated with HCC metastasis, we postulated that
increased expression of miR-125a could inhibit the invasion and
metastasis of HCC cells. As shown in Figures 3A and 3B, over-
expression of miR-125a significantly inhibited the migratory and
invasive abilities of HepG2 and HCC-LM3 cells (P , 0.01).
Consistent with the in vitro observations, the animal experiment
results showed that liver and lung metastases were apparent in
mice injected with LM3-NC cells, but few were observed in mice
injected with LM3-125a cells (Figure 3C). Histological analysis
revealed that both the number and the size of metastatic nodules
in the lungs and livers of mice were significantly lower than those
in the controls (Figure 3D; P , 0.01). Therefore, miR-125a could
repress the metastasis of HCC both in vitro and in vivo.
Down-regulation of miR-125a Inceased the Proliferation
and Invasion of SMMC-7721 Cells
To study the effects of miR-125a down-regulation on pro-
liferation and invasion of HCC, lentivirus-mediated siRNA
targeting the precursor of miR-125a was transfected into
SMMC-7721 cells, which showed relative high miR-125a
expression among HCC cell lines (Figure 1B). qRT-PCR analysis
showed that miR-125a was significantly deceased in Si-7721 cells
(Figure 4A). The results of MTT revealed that miR-125a
inhibition could promote the growth of SMMC-7721 (Figure 4B).
Both migration and invasion assays showed that the migratory and
invasive abilities of Si-7721 cells were significantly lower compared
with controls (Figure 4C).
MiR-125a Directly Down-regulated the MMP11 and
VEGF-A
To explore the mechanism underlying miR-125a involvment in
the progression and metastasis of HCC, miRanda and Pic Tar
algorithms were used to search for the target genes. The analysis
revealed several tumorigenicity-related genes as potential targets of
miR-125a, including MMP11, ERBB2, ERBB3,EDN1, VEGF-A,
MMP14 and BCL-9L. Therefore, we constructed luciferase
reporters carrying the 39-UTR with the putative miR-125a
binding sites for each of those genes. Luciferase assays showed
that the 39-UTRs of both MMP11 and VEGF-A, but not others,
caused a significant reduction in the luciferase activity (Figure 5A);
however, these effects disappeared with the deletion of key seed
regions in the 39UTR of MMP11 or VEGF-A (Figure 5B). The
miR-125a binding sites in the 39UTRs of MMP11 and VEGF-A
are shown in Figure 5C. The qRT-PCR analysis showed that the
mRNA expression levels of MMP11 and VEGF-A, were
significantly inhibited by the over-expression of miR-125a
(Figure 5D). These findings were further verified by the results
of western blot analyses, which revealed that over-expression of
miR-125a could markedly suppress MMP11 and VEGF, but not
ERBB2 or ERBB3, expression in HepG2 and HCC-LM3 cells,
and down-regulation of miR-125a could obviously increase the
expression of MMP11 and VEGF in SMMC-7721 cells
(Figure 5E). Then HCC-LM3 cells were infected with the miR-
125a lentivirus in different MOI. Western blot analysis showed
that miR-125a exhibited a dose-dependency on MMP11 and
VEGF-A expression in HCC-LM3 cells (Figure 5G).
We also asked whether miR-125a was correlated with MMP11
and VEGF-A expression in clinical HCC tissues. IHC was
performed to detect MMP11 and VEGF-A expression in HCC
samples from the 80 patients. Spearman’s rank test showed that
a significant negative correlation was found between miR-125a
and MMP11 protein expression (r=20.41, P , 0.01),and down-
regulation of miR-125a was also strongly correlated with up-
regulation of VEGF-A expression in these HCC tissues (r=20.59,
P , 0.01) (Figure 5F; Table 4).
Down-regulation of MMP11 or VEGF-A Rescued the Loss
of miR-125a Function
The expression of MMP11 and VEGF-A were markedly up-
regulated in si-7721 cells comapared with SMCC7721 cells
(Figure 5E ). To investigate whether miR-125a works through
MMP11 or VEGF-A, the siRNA of MMP11 or VEGF-A was
transfected into Si-7721 cells. Western blot showed that MMP11
or VEGF-A was significantly down-regulated in the Si-MMP11 or
Si-VEGF cells compared with Si-7721 cells (Figure 6A). MTT
assays showed that knockdown VEGF could significantly inhibit
the growth of Si-7721 cells, but inhibition of MMP11 could not
significantly influence the growth of Si-7721 cells (Figure 6B).
What’s more, RNA interference targeting MMP11 or VEGF-A
mRNA could significantly repress the migration and invasion of
Si-7721 cells (Figure 6C). These data indicated that MMP11 or
VEGF gene silencing could rescue the loss of miR-125a function
in SMMC-7721 cells.
Survival Analysis
MiR-125a, MMP11 and VEGF-A expression levels in HCC
samples were used for a survival analysis. The median survival
time of these patients was 32 months after operation. A Kaplan-
Meier analysis revealed that low miR-125a expression was
significantly associated with poor 5-year overall survival time
(25.762.7 months vs 45.462.8 months, P , 0.001) (Fig. 7A), and
that higher MMP11 expression was another significant prognostic
factor for poor survival (44.763.3 months vs 29.762.7 months,
P =0.005) (Fig. 7B). Interestingly, higher expression of VEGF-A
was also correlated with poor survival of these patients (29.862.5
months vs 4863.4 months, P=0.002) (Fig. 7C). Univariate
Table 4. The correlations of miR-125a with MMP11 and VEGF-A expression in HCC tissues.
MMP11 expression R value P value VEGF expression R Value P value
2 + 2 +
miR-125a Low 8 32 20.41 ,0.01 2 38 20.59 ,0.01
expression High 24 16 24 16
R: regression coefficient as evaluated by Pearson Correlation. P , 0.05 was considered statistically significant.
doi:10.1371/journal.pone.0040169.t004
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PLoS ONE | www.plosone.org 8 June 2012 | Volume 7 | Issue 6 | e40169Figure 6. Down-regulation of MMP11 or VEGF-A rescued the loss of miR-125a function in Si-7721 cells. (A) Western blot showed that
exprssion of MMP11 or VEGF-A was significantly repressed by each siRNA transfection. (B) MTT assays showed that knockdown VEGF could
significantly inhibit the growth of Si-7721 cells, but inhibition of MMP11 could not significantly influence the growth of Si-7721 cells. (C) RNA
interference targeting MMP11 or VEGF-A mRNA could significantly repress the migration and invasion of Si-7721 cells.
doi:10.1371/journal.pone.0040169.g006
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significantly correlated with the clinical features such as metastasis
(P , 0.001), AFP (P=0.002) and T stage (P=0.02), but not with
age, gender or HBV infection (Table 5; P . 0.05). Multivariate
regression analysis showed that AFP, but not others, was an
independent prognostic factor.
Discussion
Several studies have revealed that the expression of miRNAs is
frequently down-regulated and correlated with the malignant
progression of HCC. However, because they can post-transcrip-
tionally regulate hundreds of targets involved in several signal
transduction pathways, the roles of miRNAs in the carcinogenesis
of HCC are far from being fully be elucidated. Therefore,
exploring the clinical potential and molecular mechanism of
miRNAs underlying malignant development is significant for
beneficial therapies to delay the development and ameliorate the
living conditions of HCC patients.
Previous studies have shown that miR-125a expression was
down-regulated in several different tumors, including breast
cancer, ovarian cancer, lung cancer, medulloblastoma and gastric
cancer [11,13,14,21]. The results of human miRNA microarrays
have indicated that HCC tissues exhibit lower expression of miR-
125a [22,23]. These studies rarely focused on the prognostic values
and co-expression of miR-125a with target genes in tumor samples
from patients. In the present study, we demonstrated for the first
time that miR-125a was frequently down-regulated in HCC
compared with matched adjacent liver tissues, and that lower
expression of miR-125a was significantly associated with the
progression and poor prognosis of patients with HCC. Consistent
with the results observed in tissues, significantly lower expression
of miR-125a was observed in HCC cell lines compared with QZG
cells. Ectopic expression of miR-125a could inhibit the pro-
liferation, migration and invasion of HCC cells both in vitro and in
vivo. Inversely, down-regulating miR-125a could increase the
proliferation, migration and invasion of SMMC-7721 cells.
Interestingly, MTT assays showed that the inhibition of HCC
cell proliferation by miR-125a after culture for four days was
statistically significant; however the end point of the migration and
invasion assays was 24 h, indicating that the inhibitory effects on
cell migration and invasion were not caused by a reduction of the
cell proliferation. Therefore, further experiments are needed to
elucidate the mechanism.
MiRNA-125a can translationally arrest the mRNA of the p53
tumor suppressor gene [24], and interfere with the expression of
hepatitis B virus surface antigen [25]. Analyses using the miRanda
and Pic Tar algorithms indicated that several cancer-associated
genes including MMP11, ERBB2, ERBB3, EDN1, VEGF-A,
MMP14 and BCL-9L, were potential target genes of miR-125a.
Interestingly, over-expression of miR-125a did not significantly
repress the expression of ERBB2 or ERBB3, which were
demonstrated to be critical for inhibiting the proliferation and
metastasis of breast cancer [11]. Instead, luciferase reporter assays
confirmed that MMP11 and VEGF-A, but not other genes tested,
were targets genes of miR-125a. These findings were further
strengthened by the results of qRT-PCR and western blot
analyses. Moreover, the co-expression of miR-125a with its
targeted genes MMP11 and VEGF-A were also detected in
HCC tissues from surgical ablation. The results showed that miR-
125a was inversely correlated with both MMP11 and VEGF-A
expression in HCC tissues. Based on these data, we suspected that
miR-125a could inhibit the proliferation and metastasis of HCC
partly through down-regulating MMP11 and VEGF-A.
Previous studies have shown that increased VEGF expression in
HCC is associated with a high proliferative index, poor
Figure 7. Kaplan-Meier survival analysis and log-rank test for HCC patients. (A) Lower miR-125a expression, (B) higher MMP11 or (C) VEGF-
A, is correlated with poor 5-year cumulative survivals of the 80 HCC patients.
doi:10.1371/journal.pone.0040169.g007
Table 5. Univariate and multivariate analyses of clinical
parameters associated with prognosis.
Parameter Chi-square P value
Age 0.38 0.54
Gender 0.03 0.86
HBV 0.41 0.52
Metastasis 14.6 ,0.001
AFP 9.4 0.002
T stage 5.38 0.02
miR-125a 17.9 ,0.001
MMP11 7.85 0.005
VEGF-A 9.91 0.002
The univariate analysis shows that metastasis, AFP, T stage, miR-125a, MMP11
and VEGF-A are statistically significant prognostic factors for HCC patients.
doi:10.1371/journal.pone.0040169.t005
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thrombosis [26,27]. SiRNA targeting VEGF can inhibit HCC
growth and tumor angiogenesis in vivo [28], and has anti-tumor
efficacy for patients with HCC under hypoxic conditions [29].
Our study showed that down-regulation of MMP11 or VEGF-A
could rescue the lost of miR-125a function. VEGF expression was
significantly correlated with T stage and metastasis in HCC, and
MMP11 expression was significantly correlated with the metastasis
of HCC. What’s more, our present study showed that lentivirus-
mediated MMP11 or VEGF siRNA can rescue the lost of miR-
125a function on SMMC-7721 cells, further confirming that miR-
125a works through MMP11 or VEGF-A.
In conclusion, our present study showed that miR-125a is
frequently down-regulated and inversely correlated with aggres-
siveness and poor prognosis in HCC. Ectopic expression of miR-
125a can inhibit the proliferation, invasion and metastasis of HCC
by down-regulating MMP11 and VEGF in vitro and in vivo, and
thus, miR-125a represents a new prognosis marker and a prom-
ising approach for HCC treatment.
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